GSK3B and glioma: On the other hand, simultaneously treating U87 glioma cells with an AZD2858 (a GSK-3β inhibitor) and ICG-001, a histone acetyl transferase inhibitor that antagonizes Wnt/β-catenin/Tcf-mediated transcription by binding CBP, reduced cell proliferation and increased the cell fraction in the G0/G1 phase of the cell cycle; these effects were significantly higher in the group treated with ICQ-001 [111].